A Phase 3 study evaluating tirzepatide in adolescent participants with obesity or overweight with weight-related comorbidities reached primary completion on 2026-06-02. The trial, identified as NCT06075667, enrolled 160 participants to assess the safety and efficacy of the drug.
Background
Tirzepatide is being investigated for its potential in treating obesity and overweight in adolescents who also have weight-related comorbidities.
Trial design
This was a Phase 3 trial (NCT06075667) titled "A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities". The study is evaluating the safety and efficacy of tirzepatide once weekly in adolescents. It enrolled 160 participants with obesity or overweight with at least one weight-related comorbidity. The interventions included tirzepatide and placebo, with the study lasting approximately 90 weeks for the primary phase.
What this means
The primary completion of this Phase 3 trial for tirzepatide signifies that the main data collection period for the study's primary objectives has concluded. This milestone is a step towards potential future data analysis and reporting on the safety and efficacy of tirzepatide for adolescents with obesity or overweight and weight-related comorbidities.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, an official database of clinical studies, on 2026-06-02. The full details are available on clinicaltrials.gov under the identifier NCT06075667.